Search results
Results from the WOW.Com Content Network
In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to kidney failure. The less lipophilic statins are less prone to cause this reaction, and are probably safer to be combined with fibrates than the more lipophilic statins are. Drug toxicity includes acute ...
PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They were originally indicated for dyslipidemia of cholesterol and more recently for disorders characterized by high triglycerides.
Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins.
Drugs like Wegovy and Zepbound are approved by the U.S. Food and Drug Administration (FDA) for those with overweight or obesity and dyslipidemia. ... Fibrates. Bile acid sequestrants. Niacin.
Fibrates effectively lower serum triglycerides and raises serum HDL-cholesterol levels. [14] Although clinical benefits of fibrate treatment have been observed, the overall results are mixed and have led to reservations about the broad application of fibrates for the treatment of coronary heart disease , in contrast to statins .
It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells. [3] Gemfibrozil was patented in 1968, and came into medical use in 1982. [6] It is available as a generic medication. [4] In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million ...
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL. It was patented in 1971 and approved for medical use in 1978. [1]
However, not all PPAR agonists are fibrates, not all triglyceride-lowering agents are PPAR agonists, and not all drugs used to treat atherosclerosis lower triglycerides. A drug class is typically defined by a prototype drug, the most important, and typically the first developed drug within the class, used as a reference for comparison.